Xylar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xylar

Quick Facts

Property Description
Active ingredient Clarithromycin
Form Tablet, Suspension, Modified-release tablet
Pharmacological class Macrolide Antibiotic
Common use Counteracting Bacterial Infections
Origin Semisynthetic

What Type of Medicine is Xylar (Clarithromycin)?

Xylar is a prescription medication whose active pharmaceutical ingredient is Clarithromycin, which is universally classified as a macrolide antibiotic. This compound belongs to the broader antibacterial class of drugs and is employed to counteract the proliferation of susceptible bacteria throughout the body, a role that is widely recognized in clinical practice for respiratory and skin infections. Clarithromycin itself is a semisynthetic compound, chemically modified from its natural precursor, Erythromycin. This modification is a key differentiating feature as it grants Clarithromycin superior acid stability, improving its absorption and overall effectiveness when taken orally.


What are the Pharmaceutical Forms of Clarithromycin?

Clarithromycin is manufactured in several distinct dosage forms to accommodate various patient needs. The most common preparations include the standard tablet, the granules for oral suspension (liquid form), and the modified-release tablet designed for prolonged action. The availability of a liquid form is particularly important, often targeting pediatric patients or those who experience difficulty swallowing solid medications. While the primary method of administration is oral, the drug is also available in a sterile intravenous (IV) formulation for use in more serious clinical situations.


What is the General Purpose of This Macrolide Antibiotic?

The general purpose of Xylar is to resolve systemic ailments by stopping the growth and spread of bacterial infections, such as those affecting the respiratory tract. Clarithromycin achieves this by acting as a protein synthesis inhibitor, selectively binding to the 50S ribosomal subunit inside bacterial cells. This action prevents the bacteria from creating the essential proteins needed for survival and multiplication. By shutting down this core reproductive mechanism, the medicine halts the progression of the infection, allowing the body's natural immune system to eradicate the remaining bacteria and facilitate recovery. This mechanism is clinically established as highly effective against a broad range of pathogens.

What side effects are possible with Xylar?

Possible Side Effects and Safety Information for Xylar

Official government regulatory safety documents for Xylar outline several categories of adverse reactions and safety considerations.


Serious and Clinically Significant Adverse Reactions

The safety profile includes life-threatening allergic reactions, specifically anaphylaxis, which may occur after any dose. Other serious documented risks include significant systemic issues such as myocardial infarction (heart attack), thromboembolism (blood clots), and the development of malignancies (cancers).

Locally, the drug is associated with severe necrotic skin ulcerations, which are documented to occur following repeated exposure to the medicine.


Safety Categories by System

Adverse reactions are classified by the system-organ classes they affect, including Skin and Subcutaneous Tissue Disorders, Immune System Disorders, Cardiac Disorders, Vascular Disorders, Neoplasms, and Infections and Infestations. While common reactions may involve mild local effects, the overall safety data emphasizes the importance of monitoring for severe and uncommon systemic events.


Population and Contextual Safety Notes

The official safety information addresses specific populations and contexts of use. Regulatory documents note that in high-risk individuals, Xylar has been associated with infections, including parasitic infections. Additionally, when Xylar is present in the body alongside opioids, this co-exposure complicates the diagnosis of opioid overdose and may interfere with the expected effectiveness of standard overdose reversal treatments. Safety guidance requires cardiovascular monitoring during administration, and mandates long-term monitoring for new or worsening cancers.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Xylar

Overdose scope

Documented overdose presentations: Ingestion of large amounts of Clarithromycin can be expected to produce severe gastrointestinal symptoms, including abdominal pain, nausea, vomiting, and diarrhea. Post-marketing reports also note altered mental status, paranoia, and confusional states. Physiological systems affected (as stated in label): The cardiovascular system (risk of QT prolongation and ventricular arrhythmias), the hepatic system (risk of hepatitis and hepatic failure), and overall metabolic/fluid status (documented hypokalaemia and hypoxaemia). Dose-related or exposure-related factors (if applicable): Toxicity risk increases with higher exposure, and the drug is not significantly removed by hemodialysis or peritoneal dialysis. Population-specific overdose notes (if applicable): Elderly patients may be more susceptible to the drug's effects on the QT interval. Patients with renal impairment are at increased risk due to prolonged elimination half-life. Emergency-response statements (as written in official documents): Treatment is required to be symptomatic and supportive. Discontinuation is required immediately if signs of hepatitis or severe acute hypersensitivity reactions occur. When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention or contact a poison control center immediately upon suspected overdose.


Overdose classifications (high-level)

Severity classification (as defined in official documents): Overdose can lead to life-threatening complications, specifically citing Torsades de Pointes and fatal hepatic failure. Regulatory basis (EMA / FDA / etc.): Information is derived from the official regulatory sources. Overdose-context constraints (as defined in official documents): No specific antidote is known. Management focuses on reducing the systemic burden and supporting vital functions.


Resulting overdose structure

Official overdose statements:

  • Overdose presentations include severe gastrointestinal symptoms and can involve neuropsychiatric effects such as altered mental status and paranoia.
  • Severe outcomes documented in regulatory sources include QT interval prolongation leading to ventricular cardiac arrhythmias and Torsades de Pointes, and potentially fatal hepatic failure.
  • Management must be symptomatic and supportive, as no specific antidote is known. The drug is not significantly removed by hemodialysis or peritoneal dialysis.
  • Immediate medical attention is required upon suspected overdose, and the drug must be discontinued immediately if severe signs of acute toxicity, such as hepatitis, are observed.
  • Monitoring requirements include observation for signs of hepatic dysfunction and continuous cardiac monitoring for effects on the QT interval.

Connection to the overall overdose profile (2–4 sentences):

Official regulatory documents define the overdose profile by listing expected gastrointestinal and neuropsychiatric manifestations and strictly mandate that immediate medical attention be sought due to the risk of severe, potentially life-threatening complications, particularly cardiac arrhythmias and hepatic failure. This profile confirms that therapeutic management is confined to symptomatic and supportive measures, which must also account for known population risks such as increased cardiac susceptibility in the elderly.

Therapeutic Uses of Xylar

What Xylar Treats: Main Uses and Benefits

Xylar (Clarithromycin) is a macrolide antibiotic that is relevant in contexts marked by increased discomfort or tension, and is commonly used to help with certain bacterial infections. It is commonly used across therapeutic domains where additional symptomatic support is needed to help manage symptoms related to heightened physiological activity.

Symptom Management and Therapeutic Focus

This medication may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns affecting the respiratory tract, including pneumonia, bronchitis, and sinusitis. It is relevant when supportive symptom management is appropriate to help address symptoms related to physical discomfort and systemic imbalance, such as fever and a persistent cough. Furthermore, it is used in multi-drug therapy relevant to conditions associated with Helicobacter pylori (bacterial cause of ulcers) and Mycobacterium avium Complex (MAC). This use helps maintain a sense of stability when symptoms are more noticeable.

“Xylar is considered relevant for easing symptom clusters that may become disruptive in localized infections, providing support that helps ease the overall symptom burden.”


Quick Fact: Relief for Acute Discomfort

Symptom Axis Therapeutic Benefit
Respiratory Distress Contributes to improved comfort during periods of persistent cough and fever.
Localized Inflammation May assist with managing symptoms related to inflammatory or irritative states in skin and ear infections.
Specialized Support Helps manage the systemic burden in conditions like MAC disease.

Regulatory References

  1. NIH MedlinePlus overview of Clarithromycin

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Xylar (Clarithromycin)

The population eligibility for Xylar is strictly defined by government regulatory documents based on patient conditions and age. This macrolide antibiotic is contraindicated and must not be used by several key groups:

Classification Restricted Population Official Status
Absolute Contraindication Known Macrolide Hypersensitivity Prohibited
Absolute Contraindication History of Cholestatic Jaundice from prior Clarithromycin use Prohibited
Absolute Contraindication Known QT Prolongation or Ventricular Arrhythmia (including Torsades de Pointes) Prohibited
Absolute Contraindication Severe Hepatic Failure combined with Renal Impairment Prohibited

Eligibility is restricted for other populations. Patients with severe renal impairment (creatinine clearance < 30 mL/min) are eligible, but an official dosage reduction is required. Caution is also advised for individuals with impaired hepatic function or specific cardiac conditions like coronary artery disease.

Age-Group Rules: The medicine is established for adults and adolescents (12 years and older). For children (6 months to < 12 years), the oral suspension is the appropriate and established formulation. Safety and efficacy are not established for infants under six months of age.

Reproductive Health: Use during pregnancy is not recommended unless a physician determines the benefit outweighs the risk and no alternative is appropriate. Clarithromycin is excreted into human breast milk, and nursing must be discontinued during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Xylar (Clarithromycin) exhibits numerous officially documented interactions, primarily based on its classification as a strong inhibitor of the CYP3A4 enzyme and the efflux transporter P-glycoprotein (P-gp). This mechanistic basis leads to increased systemic exposure of many co-administered medicinal products.

Formal Interaction Constraints

The most serious constraints are formal contraindications—combinations explicitly prohibited by regulatory authorities due to the high risk of severe toxicity or adverse cardiac events, such as:

  • QT-Prolonging Agents: Astemizole, Cisapride, Pimozide, and Terfenadine.
  • Ergot Alkaloids: Ergotamine and Dihydroergotamine (risk of vasospasm).
  • Statins: Lovastatin and Simvastatin (risk of rhabdomyolysis).

Pharmacokinetic and Population Notes

The inhibition of CYP3A4 results in an officially documented increase in the plasma concentrations of various drugs, including Theophylline and Digoxin. Conversely, potent enzyme inducers like Rifampicin can significantly reduce Xylar's own serum concentrations. Population-specific cautions exist; for example, the co-administration with Colchicine is strictly contraindicated in patients with co-existing renal or hepatic impairment, as stated in the prescribing information.

Mechanism of Action

How Xylar Works

Xylar's mechanism of action is primarily executed through two distinct mechanistic domains: inhibition of bacterial protein synthesis and, secondarily, modulation of host inflammatory signaling.


Blocking Pathogen Growth via Ribosomal Targeting

This core mechanistic domain involves the drug's precise interaction with the mathbf23S ribosomal RNA on the bacterial 50S subunit. By reversibly binding and acting as an allosteric inhibitor, Clarithromycin physically blocks the polypeptide exit tunnel, which halts the elongation of essential proteins. This molecular cascade leads to the arrest of bacterial proliferation (bacteriostatic effect), which results in the containment of the microbial population, shifting the bacterial growth dynamics.


️ Modulating Localized Host Response

The secondary mechanistic domain involves the drug's influence on the host's immune signaling pathways. This effect constitutes an interaction with the production and release of cytokines and chemokines at the site of biological activity. This mechanism modulates the local inflammatory response. The mechanism contributes to the attenuation of the host's localized inflammatory cascade.

Dosage and Administration Information

Administration Overview

Xylar is typically administered under the guidance of a healthcare professional in a clinical setting. The method of delivery is designed to ensure the substance is absorbed effectively by the body's systems.

Preparation

Before the procedure begins, the healthcare provider prepares the necessary equipment. This includes ensuring the environment is sterile and that the specific required materials are organized. The individual receiving the treatment is usually positioned in a way that allows for comfortable and accurate administration.

Application Process

The process involves a systematic approach to delivery. Depending on the specific clinical requirements, the healthcare provider will follow a standardized protocol to initiate the session. During this time, the focus remains on the steady integration of the substance according to the established timeframe for the procedure.

Post-Administration

Following the completion of the administration, a period of observation is common. This allows the healthcare provider to monitor the individual's immediate response to the process. It is standard practice to remain in a rested state during this transition period until the healthcare provider indicates that the session is concluded.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xylar

Evidence for Use in Acute Respiratory and Skin Infections

Research exploring the use of Xylar (Clarithromycin) for conditions like pneumonia, bronchitis, sinusitis, and skin infections primarily involves short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were applied in studies examining patient-reported experiences of infection. Researchers monitored various endpoints, including how signs and symptoms evolved during the study period and what bacteriological and clinical outcomes the research measured. Studies monitored the clearance of the specific bacteria, known as bacteriological eradication rates, and in some studies, outcomes related to radiographic assessments were measured for pneumonia.

The finding of increasing rates of bacterial resistance is linked to varied findings across studies based on the specific strain of bacteria being treated and the geographical location. Consequently, the research describes the need for ongoing testing to confirm if a specific infection will respond. Long-term effects are not fully established beyond the short, immediate recovery phase.


Evidence for Use in Complex or Specialized Infections

Xylar has also was evaluated in studies as a component of multi-drug regimens for more specialized or complex infections. Research examined multi-drug regimens incorporating Clarithromycin in the context of Helicobacter pylori infection. Research examined specific laboratory measurements, such as the eradication rate confirmed by breath or biopsy tests, usually performed 4 to 8 weeks after the regimen was finished.

The medicine was observed in long-term, open-label clinical trials for use against Mycobacterium avium Complex (MAC), particularly in patients with underlying lung issues or those who are immunocompromised. These studies focused on complex, long-term outcomes such as culture conversion (the absence of the bacteria in repeated samples) and studies monitored the frequency of relapse or recurrence. Research describes patterns related to the length of time monitored until culture conversion was observed and the rates of treatment discontinuation observed in some studies.


Long-Term Studies and Follow-up Duration

While most research for acute infections has limited follow-up durations, specific regulatory assessments and large-scale, prospective studies have also studies explored long-term patterns, particularly in certain patient groups. In one such large study, long-term follow-up occurred for several years after a short course of Clarithromycin was completed. This research described an association with an increased rate of all-cause mortality tracked several years later in the specific Coronary Heart Disease (CHD) population studied. This finding is limited and has led to mixed findings in subsequent observational studies involving broader populations. The scientific basis for this delayed pattern is not fully established.


What Is Still Uncertain About the Research

Research provides context about the types of evidence that exist for Xylar, but evidence also highlights several areas where certainty remains low or where further study is needed. The ongoing presence of antibiotic resistance means that certainty about measured outcomes remains low. Comparative evidence is lacking for the long-term findings in other groups. Finally, the evidence quality varies across studies, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
  2. Disseminated Mycobacterium avium Complex: Adult and Adolescent OIs | NIH - Clinical Info .HIV.gov (Clarithromycin as part of MAC regimen)
  3. Clarithromycin 500 mg extended-release in the management of patients with upper respiratory tract infection (Post-marketing observational data on outcomes/symptoms)

Frequently Asked Questions (FAQ)

Common questions about Xylar (FAQ)


Q: Is Xylar similar to other common medicines for this condition?

The active ingredient in Xylar, Clarithromycin, is described as a semisynthetic compound that is chemically related to the older antibiotic Erythromycin. Official information indicates that Xylar was modified to have superior acid stability, which improves its absorption and overall effectiveness when it is taken orally.


Q: How quickly should I expect Xylar to start working?

For infections, official patient information often indicates that individuals may begin to see an improvement in symptoms during the first few days of treatment. If symptoms do not show this potential improvement or if they worsen during this time, consultation with a healthcare professional is appropriate.


Q: Does Xylar cause weight gain or loss?

Weight changes, such as gain or loss, are not listed as common or severe adverse reactions in the official prescribing information for human use. Regulatory documents do, however, mention that animal reproductive studies observed reduced body-weight gain in offspring.


Q: Can Xylar affect my sleep patterns?

Sleep disturbances, specifically insomnia (difficulty sleeping), are reported as an adverse reaction in some safety surveillance data related to Xylar's active ingredient. If changes in sleep patterns are noted, seeking guidance from a healthcare professional is appropriate.


Q: Are there any long-term effects associated with taking Xylar?

Regulatory documents include a specific warning noting that, in certain high-risk groups like people with coronary artery disease, there may be an increased risk of death for any reason tracked several years after a course of the medicine is completed. The reason for this long-term pattern is not fully known, and the finding specifically relates to that patient group.


Q: Is it safe to take Xylar with basic over-the-counter pain relievers?

Official medication safety checkers generally indicate that there is no known major interaction documented between Xylar (Clarithromycin) and common over-the-counter pain relievers, such as ibuprofen. Consultation with a healthcare professional before co-administration is a prudent measure.


Q: What happens if I forget a dose of Xylar?

If a dose is forgotten, general patient instructions advise taking the missed dose as soon as it is remembered. If it is nearly time for the next scheduled dose, official instructions advise skipping the missed dose and continuing with the regular schedule, and to not take a double dose to compensate.


Q: Is Xylar safe for older adults or seniors?

Official prescribing guidance notes that due to the potential for gastrointestinal intolerance in older patients, a dose reduction may be considered for patients over the age of 70 years. Caution may be appropriate for older individuals who have pre-existing conditions like kidney impairment.


Q: Will Xylar interfere with my birth control or hormone medication?

Xylar is known to inhibit the CYP3A4 enzyme, which can increase the concentration of other drugs, including the hormones in many oral contraceptives. While some studies suggest no significant interference with the anti-ovulatory effect, professional guidance may recommend the use of a back-up birth control method during treatment.


Q: Are there any foods or drinks I need to avoid while on Xylar?

The extended-release tablet formulation is specified to be taken with food. Additionally, official information strongly advises against the consumption of grapefruit juice, as it can interfere with the breakdown of the medicine in the body by inhibiting the CYP3A4 enzyme.


Q: Does Xylar make you feel tired or drowsy?

While drowsiness is not typically listed as a common general side effect, a specific warning exists regarding co-administration with certain sedating medicines, such as benzodiazepines. When combined, Xylar may cause an individual to feel more sedated and drowsy.


Q: Is there evidence that Xylar is effective for its stated purpose?

Yes, regulatory documents confirm that effectiveness is supported by evidence from short-term Randomized Controlled Trials (RCTs) and systematic reviews. Studies have examined endpoints like bacteriological eradication rates and monitored the evolution of signs and symptoms of infection.


Q: How soon after stopping Xylar does it leave the body?

Pharmacokinetic data from regulatory documents shows that the main active metabolite of Xylar, 14-OH clarithromycin, has an elimination half-life that typically ranges from 5 to 9 hours. This measurement describes the rate at which the medicine’s concentration in the body reduces by half.


Q: Does Xylar interact with herbal supplements like St. John's Wort?

Regulatory information lists drug inducers that can reduce Xylar's effectiveness. Since St. John's Wort is a known potent enzyme inducer of CYP3A4, it may lead to decreased concentrations of Xylar in the body. Consultation with a healthcare professional regarding any herbal supplement is recommended.


Q: Is a metallic taste or dry mouth a common side effect of Xylar?

A change in taste, which is frequently described as a metallic taste, is listed in official safety documents as one of the most common side effects of Xylar. Other common effects include abdominal pain and diarrhea. Dry mouth is not typically listed among the most common adverse effects.


Q: What should I do if the medicine does not seem to be working?

If symptoms of the infection do not improve or if they become worse during the first few days of treatment, contacting a healthcare professional is appropriate. The medicine should not be stopped unless instructed by a professional.


Q: Are there different strengths of Xylar available?

Yes, official regulatory documents state that Xylar is supplied in multiple forms and strengths. These include immediate-release tablets in 250 mg and 500 mg strengths, extended-release tablets in a 500 mg strength, and granules that are used to create an oral suspension (liquid form).


Q: Is Xylar described as a life-long treatment or short-term use?

For the majority of common acute bacterial infections, Xylar is prescribed for short-term use, typically for a duration of 7 to 14 days. However, regulatory documents describe that for certain complex or chronic infections, Xylar can be used as part of a multi-drug regimen that continues for a much longer duration.


Q: What kind of monitoring is typically done when taking Xylar?

Standard monitoring may involve checking for signs of hypersensitivity or liver problems. For prolonged therapy or in high-risk patients, official guidance recommends more detailed monitoring, which can include checks for hearing function and specific laboratory tests.


Q: Do studies suggest Xylar's effectiveness is consistent across different patient groups?

While effectiveness has been measured across different populations, research indicates a link between varied findings and increasing rates of bacterial resistance based on the specific strain of bacteria being treated. This suggests that the likelihood of success may vary depending on the geographical location and the specific infection being addressed.


Q: Is it common to feel nauseous when first starting Xylar?

Yes, official safety documents list nausea as one of the most common gastrointestinal side effects associated with Xylar. The extended-release tablet is specified to be taken with food, which may help reduce stomach irritation.


Q: Can Xylar affect my ability to drive or operate machinery?

Official consumer information advises that individuals should be careful driving or operating machinery until they are aware of how Xylar affects them. Side effects such as dizziness, confusion, or visual disturbances have been reported in some cases.


Q: Are there any known severe but rare side effects of Xylar?

Yes, official safety documents list several severe adverse events, including potentially life-threatening anaphylaxis (severe allergic reaction), myocardial infarction (heart attack), and the development of malignancies (cancers). These serious events are subject to the strictest regulatory warnings.


Q: How long does Xylar's effect typically last after one dose?

Xylar is typically prescribed to be taken twice a day (every 12 hours) or once a day for the extended-release formulation. This routine dosing schedule is officially designed to maintain a consistent concentration of the medicine in the body to sustain its antibacterial effect.


Q: Is it safe to stop taking Xylar suddenly?

Patient instructions caution that individuals continue taking the medicine until the entire prescribed course is finished, even if symptoms improve quickly. Stopping treatment should not occur unless directed by a healthcare professional, as stopping too early may result in the infection not being completely treated.


Q: Does Xylar change the way other medications are processed in the body?

Yes, Xylar's active ingredient is officially documented as a strong inhibitor of the CYP3A4 enzyme and the transporter P-glycoprotein (P-gp). This mechanism can significantly increase the concentration of many other co-administered medications in the body, which raises the potential for toxicity.


Q: Can Xylar cause mood changes or unusual behavior?

While not listed as a common effect, safety surveillance data and case reports have described rare instances of neuropsychiatric adverse effects associated with macrolide antibiotics. These reported symptoms include confusion, hallucinations, or unusual behavior.


Q: Does Xylar have any known interaction with caffeine?

Xylar is known to inhibit the CYP3A4 enzyme which is responsible for breaking down caffeine in the body. This inhibition may lead to a decreased metabolism of caffeine and could result in increased caffeine levels in the body, potentially causing symptoms like nervousness or heart rate changes.


Q: Is there a maximum time frame for how long Xylar can be taken?

The maximum duration of treatment depends on the infection being treated. While acute regimens are short (e.g., 7-14 days), regulatory documents describe that for certain chronic or complex infections, Xylar may be used as part of a multi-drug regimen that can be continued indefinitely.


Q: Does the medicine need to be stored in a special way?

Yes, specific storage conditions are mandated by official documents. The tablets must be kept at controlled room temperature (20 C to 25 C) in their original container and protected from light. The reconstituted liquid suspension must not be refrigerated and must be used within 14 days of mixing.


Q: Can taking Xylar lead to skin sensitivity or sun reactions?

Official safety documents list Skin and Subcutaneous Tissue Disorders among the possible categories of adverse events, including severe necrotic skin reactions. Other macrolide antibiotics have also been associated with photosensitivity (increased skin sensitivity to sunlight) which may be a consideration.


Q: Why is Xylar restricted to prescription-only use?

The prescription-only status is due to the drug's significant risk profile and the necessity for professional oversight. This profile includes numerous serious contraindications (such as heart rhythm issues), complex drug interactions (due to CYP3A4 inhibition), and the critical need for appropriate use to combat antibiotic resistance.

How should Xylar be stored and disposed of?

How to Store and Dispose of Xylar (Clarithromycin)

Official regulatory guidelines specify distinct storage and handling requirements to maintain the stability and effectiveness of Xylar.

️ Storage and Stability

  • Tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
  • The medication must be kept in its tightly closed, original container and protected from light.
  • The reconstituted oral suspension has a limited stability period and must not be refrigerated; it must be used within 14 days of mixing.
  • It is mandatory to keep this medicine out of the reach and sight of children.

️ Disposal Requirements

Any remaining liquid suspension after the 14-day stability period must be safely discarded. For unused or expired tablets, disposal must follow official governmental guidelines, such as those provided by the FDA for unused medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xylar found in:

A-Z Index: